XOMA Royalty Corporation (XOMAP) Stock Analysis & Winston Score

XOMA Royalty Corporation is a biotechnology royalty company. Instead of making drugs itself, it buys the rights to receive future royalty payments from other companies that are developing or selling medicines. When those drugs get approved and start selling, XOMA collects a share of the revenue without having to run clinical trials or manufacture anything. XOMA makes money by acquiring royalty interests and milestone rights tied to drug candidates across many different biotech and pharmaceutical partners. It operates primarily in the United States and has a small market cap of around $300 million. Its business model creates a naturally high gross margin, since collecting royalties costs very little once the rights are purchased. The main risk is that its income depends entirely on whether partner drugs succeed in clinical trials and reach the market — if those drugs fail or sell poorly, XOMA's royalty streams shrink, making its future cash flows difficult to predict.